Board Change • May 20
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 3 experienced directors. No highly experienced directors. Independent Director Xiaoyan Huang is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Apr 28
CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 18, 2026 CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 18, 2026, at 15:00 China Standard Time. Location: The Company's Meeting Room, Shenzhen, Guangdong China Duyuru • Mar 31
CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Duyuru • Dec 31
CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 Duyuru • Sep 30
CGN Nuclear Technology Development Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 CGN Nuclear Technology Development Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Duyuru • Jul 02
CGN Nuclear Technology Development Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 CGN Nuclear Technology Development Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Duyuru • Jun 09
CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, Jun 30, 2025 CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, Jun 30, 2025, at 14:30 China Standard Time. Location: 19F, North Tower, No. 2002, Shennan Avenue, Futian District, Shenzhen, Guangdong China Duyuru • Apr 01
CGN Nuclear Technology Development Co., Ltd. Approves the Election of Yu Haifeng as Non-Independent Director CGN Nuclear Technology Development Co., Ltd. held its 2nd Extraordinary General Meeting of 2025 on 28 March 2025, during which the following proposal(s) was/were approved: Election of Yu Haifeng as a non-independent director. Duyuru • Mar 31
CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Duyuru • Feb 18
CGN Nuclear Technology Development Co., Ltd. Approves Board Elections CGN Nuclear Technology Development Co., Ltd. at its Extraordinary General Meeting held on 14 February 2025, approved the election of Wang Man and He Fei as non-independent director. Duyuru • Dec 31
CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.001 profit in 3Q 2023) Third quarter 2024 results: CN¥0.05 loss per share (down from CN¥0.001 profit in 3Q 2023). Revenue: CN¥1.67b (flat on 3Q 2023). Net loss: CN¥47.8m (down CN¥48.7m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance. Duyuru • Sep 30
CGN Nuclear Technology Development Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 CGN Nuclear Technology Development Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Duyuru • Aug 30
CGN Nuclear Technology Development Co., Ltd. Approves Election of Mou Wenjun as A Non-Independent Director CGN Nuclear Technology Development Co., Ltd. held its Extraordinary General Meeting of 2024 on 28 August 2024 approved Election of Mou Wenjun as a non-independent director. Duyuru • Jun 29
CGN Nuclear Technology Development Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 CGN Nuclear Technology Development Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Duyuru • Apr 29
CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 17, 2024 CGN Nuclear Technology Development Co., Ltd., Annual General Meeting, May 17, 2024, at 14:30 China Standard Time. Location: 19F, North Tower, No. 2002, Shennan Avenue, Futian District, Shenzhen, Guangdong China Duyuru • Mar 30
CGN Nuclear Technology Development Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 CGN Nuclear Technology Development Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Duyuru • Jan 16
CGN Nuclear Technology Development Co., Ltd. Approves Board Elections CGN Nuclear Technology Development Co., Ltd. announced that at its EGM held on 12 January 2024, the shareholders approved election of Mu Changkun and Wu Yuanming as non-independent directors of the company. Duyuru • Dec 30
CGN Nuclear Technology Development Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 CGN Nuclear Technology Development Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 New Risk • Dec 21
New major risk - Revenue and earnings growth Earnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 242% Earnings have declined by 23% per year over the past 5 years. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.092 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.092 in 3Q 2022). Revenue: CN¥1.68b (down 23% from 3Q 2022). Net income: CN¥939.9k (down 99% from 3Q 2022). Profit margin: 0.1% (down from 4.0% in 3Q 2022). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 26
Second quarter 2023 earnings released: CN¥0.084 loss per share (vs CN¥0.091 profit in 2Q 2022) Second quarter 2023 results: CN¥0.084 loss per share (down from CN¥0.091 profit in 2Q 2022). Revenue: CN¥1.64b (down 30% from 2Q 2022). Net loss: CN¥78.9m (down 192% from profit in 2Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Duyuru • Jun 02
CGN Nuclear Technology Development Co., Ltd. Announces Cash Dividend of A Shares for the Year 2022, Payment Date Is 07 June 2023 CGN Nuclear Technology Development Co., Ltd. announced cash dividend/10 shares (tax included) of CNY 0.4000000 of A shares for the year 2022. Record date is 06 June 2023. Ex-date is 07 June 2023. Payment date 07 June 2023. Reported Earnings • Apr 28
First quarter 2023 earnings released: CN¥0.027 loss per share (vs CN¥0.04 profit in 1Q 2022) First quarter 2023 results: CN¥0.027 loss per share (down from CN¥0.04 profit in 1Q 2022). Revenue: CN¥1.23b (down 38% from 1Q 2022). Net loss: CN¥25.7m (down 168% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Board Change • Feb 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Employee Supervisor Jun Wang was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jan 21
CGN Nuclear Technology Development Co., Ltd. Approves Management Elections CGN Nuclear Technology Development Co., Ltd. at its Extraordinary General Meeting held on 19 January 2023 approved election of Sheng Guofu and Wen Zhitao as non-independent director, Huang Xiaoyan and Kang Xiaoyue as independent director and Yang Jun and Wang Jun as non-employee supervisor. Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Chengqing Liu is the most experienced director on the board, commencing their role in 2020. Independent Director Guangguo Sun was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 31
Third quarter 2022 earnings released: EPS: CN¥0.092 (vs CN¥0.079 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.092 (up from CN¥0.079 in 3Q 2021). Revenue: CN¥2.17b (up 1.2% from 3Q 2021). Net income: CN¥87.5m (up 17% from 3Q 2021). Profit margin: 4.0% (up from 3.5% in 3Q 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 28
Second quarter 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.11 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.091 (down from CN¥0.11 in 2Q 2021). Revenue: CN¥2.35b (up 24% from 2Q 2021). Net income: CN¥85.7m (down 19% from 2Q 2021). Profit margin: 3.6% (down from 5.6% in 2Q 2021). Over the next year, revenue is forecast to grow 3.1%, compared to a 39% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 5% per year. Reported Earnings • May 02
First quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.025 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.04 (up from CN¥0.025 in 1Q 2021). Revenue: CN¥1.96b (up 37% from 1Q 2021). Net income: CN¥38.1m (up 63% from 1Q 2021). Profit margin: 1.9% (up from 1.6% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 1.1%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat. Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥7.95, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 14x in the Chemicals industry in China. Total loss to shareholders of 11% over the past three years. Board Change • Apr 27
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 4 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Chengqing Liu is the most experienced director on the board, commencing their role in 2020. Independent Director Guangguo Sun was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Mar 05
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥10.24, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 14% over the past three years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.079 (vs CN¥0.058 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥2.14b (up 21% from 3Q 2020). Net income: CN¥74.7m (up 37% from 3Q 2020). Profit margin: 3.5% (up from 3.1% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.28 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥1.90b (down 6.3% from 2Q 2020). Net income: CN¥106.0m (down 59% from 2Q 2020). Profit margin: 5.6% (down from 13% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Reported Earnings • May 02
First quarter 2021 earnings released: EPS CN¥0.025 (vs CN¥0.066 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.43b (up 53% from 1Q 2020). Net income: CN¥23.4m (up CN¥85.6m from 1Q 2020). Profit margin: 1.6% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Reported Earnings • Apr 17
Full year 2020 earnings released: EPS CN¥0.29 (vs CN¥0.10 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥6.65b (down 5.3% from FY 2019). Net income: CN¥271.1m (up 164% from FY 2019). Profit margin: 4.1% (up from 1.5% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Mar 16
New 90-day high: CN¥12.08 The company is up 41% from a price of CN¥8.56 on 16 December 2020. Outperformed the Chinese market which is down 2.0% over the last 90 days. Exceeded the Chemicals industry, which is up 10.0% over the same period. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥9.32, the stock is trading at a trailing P/E ratio of 31.5x, down from the previous P/E ratio of 37.3x. This compares to an average P/E of 34x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 14%. Is New 90 Day High Low • Jan 15
New 90-day high: CN¥11.22 The company is up 14% from its price of CN¥9.80 on 16 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥49.63 per share. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥10.73, the stock is trading at a trailing P/E ratio of 36.9x, up from the previous P/E ratio of 30.4x. This compares to an average P/E of 35x in the Chemicals industry in China. Total return to shareholders over the past three years is a loss of 18%. Is New 90 Day High Low • Dec 29
New 90-day high: CN¥10.73 The company is up 13% from its price of CN¥9.50 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥8.81 The company is down 5.0% from its price of CN¥9.23 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 2.0% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥280.7m, up 37% from the prior year. Total revenue was CN¥7.10b over the last 12 months, up 6.7% from the prior year.